Abstracts

Pathological primary tumour and lymph node regression following neoadjuvant chemotherapy in resectable oesophagogastric cancer: Pooled analysis of 1619 patients from two randomised trials

Background No definitive largescale data exists evaluating the role of pathologically defined regression changes within lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma ...

Naureen Starling , MBBS, MD;

A. Athauda ;

M. Nankivell ;

S. Pritchard ;

R. Langer ;

R. Langley ;

K. Von Loga ;

I. Chau ;

David Cunningham ;

H. Grabsch ;

06/30/2022

Individual participant data network meta-analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma

Background The optimal neoadjuvant treatment for resectable locally advanced carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. Moreo...

Matthieu Faron ;

Maurice Cheugoua-Zanetsie ;

Pierre Thirion ;

Jayne Tierney ;

Kathryn Winter ;

Jianhua Fu ;

David Cunningham ;

Muriel Mauer ;

06/30/2022

Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer

Background Despite advances in perioperative care, esophageal cancer patients undergoing esophagectomy have a high risk of postoperative major morbidity and death. We sought to determine...

06/30/2022

Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)

Background The potential predictive value of soluble checkpoint molecules for immune checkpoint inhibitor has been shown in several malignancies including non-small cell lung cancer and ...

06/30/2022

Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial

Background In up to 20% of patients (pts), GC/GEJA is HER2 positive. T-DXd is an antibody-drug conjugate composed of a humanized anti-HER2 monoclonal antibody, tetrapeptide-based cleavab...

06/30/2022

Disease-free survival as surrogate for overall survival in neoadjuvant chemo(radio)therapy treatment of esophageal or gastro-esophageal junction carcinoma: An analysis of 4518 individual patients and 22 trials

Background The use of disease-free survival (DFS) as a surrogate endpoint for overall survival may speed up clinical research in cancer trials. Validation of DFS as surrogate for OS in n...

06/30/2022

Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma

Background Biliary tract cancers (BTCs) are rare malignancies with a poor prognosis and scarce therapeutic strategies. The BRCAness phenotype has been shown to correlated with a good res...

06/29/2022

Comparison of resected vs non-resected patients with unresectable locally advanced pancreatic cancer (LAPC) receiving P-32 microparticles with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy in the PanCO study

Background Unresectable LAPC has a poor prognosis. Current standard-of-care (SoC) is limited to chemotherapy or chemo-radiotherapy. Brachytherapy using a device containing beta-radiation...

06/29/2022

Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma

Background KRAS mutation is the most common molecular alteration in pancreatic adenocarcinoma (PDAC). However, 8-10% of patients harbor KRAS wild-type tumors (WT). The objectives of this...

A. Hollebecque ;

06/29/2022

Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer

Background Botensilimab (BOT) promotes optimized T cell priming, activation and memory formation by strengthening antigen presenting cell/T cell co-engagement. As a fragment crystallizab...

06/29/2022